drugset / Trial / NCT06466265
Study of DNP002 in Patients With Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is an open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6) antibody DNP002 in patients with advanced solid tumors.
Timeline
- Start
- 2021-05-24
- Primary completion
- 2024-12
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DNP002 | Unknown | — | Intravenous |
Indications
No indication recorded.